The hyperpolarization-activated cyclic nucleotide-gated (HCN) channel family, comprising four isoforms (HCN1-4), regulates electrical activity in excitable tissues. HCN2. encoded by the *HCN2* gene, is a voltage-gated ion channel that contributes to pacemaker currents (Ih) in the heart and brain. It is activated by membrane hyperpolarization and modulated by cyclic nucleotides (e.g., cAMP), linking cellular signaling to electrical excitability. In the heart, HCN2 influences sinoatrial node activity and heart rate regulation. In neurons, it modulates resting membrane potential, synaptic integration, and rhythmic activity in thalamocortical and hippocampal circuits.
HCN2 antibodies are essential tools for studying the expression, localization, and function of HCN2 channels. These antibodies are typically developed using immunogenic peptides derived from specific regions of the HCN2 protein (e.g., N-terminal, C-terminal, or intracellular domains). Validation involves techniques like Western blotting, immunohistochemistry, and knockout tissue controls to ensure specificity. Applications include investigating HCN2 distribution in cardiac tissue, neuronal subtypes, or disease models, such as epilepsy, neuropathic pain, or cardiac arrhythmias. Dysregulation of HCN2 has been implicated in pathologies like sinus bradycardia and absence seizures, making its antibody a critical reagent for both basic research and therapeutic target validation. Commercial HCN2 antibodies vary in host species, clonality, and conjugation, enabling flexible experimental designs.